METHOD FOR COMBINED TREATMENT OF OPERABLE STOMACH CANCER WITH HYPEREXPRESSION OF HER2/neu Russian patent published in 2021 - IPC A61K31/337 A61K31/282 A61K31/513 A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, specifically to oncology. The method for combined treatment of operable stomach cancer with hyperexpression of HER2neu includes conducting chemotherapy following the FLOT plan: docetaxel at a dose of 50 mg/m² by intravenous drop infusion on day 1, oxaliplatin at a dose of 85 mg/m² by intravenous drop infusion on day 1, with the duration of the infusion of 2 hours, leucovorin at a dose of 200 mg/m² by intravenous drop infusion on day 1, with the duration of the infusion of 2 hours, 5-fluorouracil 2,600 mg/m² with an interval between the courses of 14 days, combined with intravenous drop infusion of trastuzumab, and operative treatment. Infusion of 5-fluorouracil is therein conducted for 48 hours. Trastuzumab is introduced at a dose of 4 mg/kg by intravenous drop infusion on day 1 with an additional loading dose of 6 mg/kg. All eight courses of targeted and chemotherapy are conducted prior to operative treatment.

EFFECT: invention improves the results of combined treatment of gastric cancer by eliminating undesirable events of radiation therapy and reducing the frequency of postoperative complications.

1 cl, 1 ex